English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/227819
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Targeting the CRD F‐face of human galectin‐3 and allosterically modulating glycan binding by angiostatic PTX008 and a structurally optimized derivative

AuthorsMiller, Michelle C.; Zheng, Yi; Suylen, Dennis; Ippel, Hans; Cañada, F. Javier CSIC ORCID ; Berbís, Manuel Álvaro CSIC; Jiménez-Barbero, Jesús CSIC ORCID; Tai, Ghihua; Gabius, Hans-Joachim; Mayo, Kevin H.
KeywordsAngiogenesis
Calixarenes
Drug design
Galectin · metastasis
Issue Date6-Nov-2020
PublisherJohn Wiley & Sons
CitationChemMedChem 15:1-12 (2020)
AbstractCalix[4]arene PTX008 is an angiostatic agent that inhibits tumor growth in mice by binding to galectin‐1, a β‐galactoside‐binding lectin. To assess the affinity profile of PTX008 for galectins, we used 15N,1H HSQC NMR spectroscopy to show that PTX008 also binds to galectin‐3 (Gal‐3), albeit more weakly. We identified the contact site for PTX008 on the F‐face of the Gal‐3 carbohydrate recognition domain. STD NMR revealed that the hydrophobic phenyl ring crown of the calixarene is the binding epitope. With this information, we performed molecular modeling of the complex to assist in improving the rather low affinity of PTX008 for Gal‐3. By removing the N‐dimethyl alkyl chain amide groups, we produced PTX013 whose reduced alkyl chain length and polar character led to an approximately eightfold stronger binding than PTX008. PTX013 also binds Gal‐1 more strongly than PTX008, whereas neither interacts strongly, if at all, with Gal‐7. In addition, PTX013, like PTX008, is an allosteric inhibitor of galectin binding to the canonical ligand lactose. This study broadens the scope for galectin targeting by calixarene‐based compounds and opens the perspective for selective galectin blocking.
Description12 p.-8 fig.
Publisher version (URL)https://doi.org/10.1002/cmdc.202000742
URIhttp://hdl.handle.net/10261/227819
DOIhttp://dx.doi.org/10.1002/cmdc.202000742
ISSN1860-7179
E-ISSN1860-7187
Appears in Collections:(CIB) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdfRestringido15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.